Amgen
Compare Amgen…Large-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AmgenLarge-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026.
MariTide: differentiated antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, designed for monthly or less frequent dosing. Phase 3 readout expected late 2026, BLA filing late 2026 to early 2027.